Wound Care in Patients with Substance Use Disorders

Wound care in patients with substance use disorders (SUDs) requires clinical skill, non-judgmental communication, and coordinated care that most wound care training programs do not adequately prepare clinicians to deliver. Patients with SUDs present with wound types, infection patterns, pain management complexities, and care coordination needs that differ substantively from the general wound care population. Stigma — from both the healthcare system and the patient's own experience — is the single largest barrier to effective care.

Injection drug use is responsible for a growing proportion of wound care presentations in emergency departments, mobile wound care settings, and home health visits. Methamphetamine, opioids, and other injected substances cause direct tissue injury, introduce bacteria into deep tissue planes, and impair the immune and nutritional status required for wound healing. The wound care clinician who can navigate these challenges effectively serves a population with some of the highest unmet healthcare needs in the country.

Injection Site Wounds

Injection drug use creates wounds through multiple mechanisms, and understanding the mechanism informs the treatment approach.

Types of Injection Site Injuries

Skin and soft tissue infections (SSTIs): The most common wound care presentation in injection drug users. Bacteria are introduced through non-sterile injection technique — contaminated needles, unclean skin, and the use of non-sterile diluents (tap water, saliva) to dissolve substances. Abscesses, cellulitis, and phlegmon are the typical presentations.

Skin popping injuries: When intravenous access is no longer available, users inject subcutaneously or intramuscularly ("skin popping"). This creates deposits of substance and bacteria in tissue planes that are poorly vascularized, producing chronic wounds with necrotic bases, sinus tracts, and indolent infection.

Vascular injury: Repeated injection into the same venous access site causes sclerosis, thrombosis, and eventual vessel destruction. Patients inject into progressively smaller or more dangerous vessels — femoral, jugular, dorsal hand — increasing the risk of arterial injection (causing distal ischemia), deep vein thrombosis, and pseudoaneurysm.

Chemical injury: Some injected substances — particularly crushed oral medications, methamphetamine prepared with corrosive adulterants, and black tar heroin — cause direct chemical necrosis of surrounding tissue independent of any infectious process.

Assessment Priorities

When assessing injection site wounds, evaluate for depth of involvement (superficial abscess vs. deep space infection or necrotizing fasciitis), vascular compromise distal to the wound, compartment syndrome in extremity wounds, and retained foreign bodies (needle fragments). Crepitus, rapid progression of erythema, and pain disproportionate to the visible wound are red flags for necrotizing soft tissue infection requiring emergency surgical consultation.

MRSA Risk and Infection Management

Methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection rates are significantly elevated in the injection drug use population. Community-associated MRSA (CA-MRSA) strains — particularly USA300 — are the dominant pathogens in injection-related SSTIs.

Clinical Management

Empiric coverage: Wound cultures should guide definitive therapy, but initial empiric antibiotic selection for injection site infections should include MRSA coverage. Trimethoprim-sulfamethoxazole and doxycycline are first-line oral options for uncomplicated CA-MRSA SSTIs. Vancomycin is the standard parenteral option for hospitalized patients with severe SSTIs.

Incision and drainage (I&D): For fluctuant abscesses, I&D remains the primary treatment. Antibiotic therapy alone without I&D is inadequate for established abscesses. Pack the cavity loosely to prevent premature closure and schedule close follow-up for repacking.

Wound cultures: Always obtain wound cultures from injection site abscesses and infected wounds in this population. Polymicrobial infections are common, and culture results may reveal organisms (anaerobes, oral flora from saliva used as diluent) that require targeted therapy.

Endocarditis screening: Patients with injection drug use who present with SSTIs and concurrent fever, new heart murmur, or embolic phenomena require evaluation for infective endocarditis. This is not within the wound care clinician's scope to diagnose, but recognizing the warning signs and ensuring appropriate referral is essential.

Pain Management Challenges

Pain management in patients with substance use disorders is one of the most difficult aspects of wound care in this population. The clinician must balance the patient's right to adequate pain management against the risks of opioid prescribing in a patient with an active or historical opioid use disorder.

Guiding Principles

Pain is real: Patients with SUDs experience genuine wound pain. The assumption that drug-seeking behavior explains all pain complaints is clinically incorrect and leads to undertreatment that drives patients away from care.

Tolerance is physiological: Patients with chronic opioid exposure (whether from prescribed opioids or illicit use) develop physiological tolerance. Standard analgesic doses may be insufficient. This is a pharmacological reality, not a behavioral problem.

Non-opioid multimodal analgesia first: Maximize non-opioid pain management before considering opioids. Options include topical lidocaine at the wound site, oral acetaminophen and NSAIDs (when not contraindicated), gabapentin or pregabalin for neuropathic wound pain, and regional nerve blocks for procedural pain during debridement.

Buprenorphine/naloxone (Suboxone) coordination: Patients on medication-assisted treatment (MAT) with buprenorphine/naloxone for opioid use disorder present specific pain management challenges because buprenorphine's partial agonist properties complicate the use of full agonist opioids. Do not discontinue MAT for wound pain management. Coordinate with the patient's addiction medicine provider for pain strategies that maintain MAT stability.

Motivational Interviewing in Wound Care

Motivational interviewing (MI) is an evidence-based communication technique that the wound care clinician can use to engage patients with SUDs in their wound care without confrontation or judgment.

Core MI Principles for Wound Care

Express empathy: Acknowledge the patient's situation without judgment. "I can see this wound is causing you a lot of pain" is more effective than any statement that implies the wound is the patient's fault.

Develop discrepancy: Help the patient recognize the gap between their current wound status and their goals. "You mentioned wanting to get back to work — what do you think is getting in the way of this wound healing?" invites the patient to identify their own barriers.

Roll with resistance: When patients resist treatment recommendations, do not argue. Resistance is a signal to change approach, not to push harder. "It sounds like the dressing changes are hard to fit into your day. What would make that easier?" explores solutions rather than demanding compliance.

Support self-efficacy: Reinforce the patient's capacity to participate in their own care. Acknowledge every positive step — attending the appointment, allowing wound assessment, completing a dressing change.

Harm Reduction and Wound Prevention

Harm reduction accepts that substance use may continue and focuses on reducing the medical consequences rather than requiring abstinence as a precondition for care.

Safer injection education: For patients who continue to inject, education on sterile technique reduces wound risk. Use new needles for every injection, clean the injection site with alcohol, avoid injecting into wounds or damaged skin, rotate injection sites, and never share needles. Wound care clinicians can provide this education without endorsing drug use.

Needle exchange and syringe services: Connect patients with local syringe service programs (SSPs) that provide sterile injection equipment, wound care supplies, naloxone, and referrals to treatment. SSPs have documented efficacy in reducing injection-related SSTIs, HIV, and hepatitis C transmission.

Naloxone distribution: Ensure patients who use opioids and their close contacts have access to naloxone for overdose reversal. Many wound care visits occur in settings where naloxone can be distributed or prescribed.

Wound care kits: Basic wound care supplies — adhesive bandages, sterile gauze, antiseptic wipes, and wound care instructions — can be assembled and distributed to patients for self-management between clinical visits. Meeting patients where they are includes equipping them to care for minor wounds independently.

Coordination with Addiction Services

Wound care visits represent a healthcare touchpoint for patients who may have limited engagement with other medical services. The wound care clinician has an opportunity — not an obligation to coerce, but an opportunity to offer — connection to addiction treatment services.

Warm handoffs: When a patient expresses interest in treatment, facilitate a direct connection rather than providing a phone number. Call the treatment program with the patient present, introduce them, and schedule the intake. A warm handoff dramatically increases follow-through compared to a cold referral.

Medication-assisted treatment access: Buprenorphine can be prescribed by any DEA-licensed practitioner. If your organization includes prescribers with buprenorphine training, wound care visits can serve as an entry point to MAT for interested patients.

Chronic pain coordination: Many patients with SUDs and chronic wounds live with chronic pain that predates and contributes to their substance use. Coordinating a pain management plan that addresses wound pain without destabilizing recovery requires communication between the wound care provider, the addiction medicine provider, and the primary care provider.

Key Takeaways

Injection site wounds result from non-sterile technique, chemical tissue injury, and vascular damage — understanding the mechanism informs treatment, and assessment must include evaluation for deep space infection, necrotizing fasciitis, and compartment syndrome.
MRSA is the dominant pathogen in injection-related soft tissue infections, and empiric antibiotic selection must include MRSA coverage while wound cultures guide definitive therapy.
Pain management requires balancing adequate analgesia with SUD risk — maximize non-opioid multimodal approaches, never discontinue MAT for wound pain, and coordinate with addiction medicine providers for patients on buprenorphine.
Motivational interviewing techniques (empathy, developing discrepancy, rolling with resistance, supporting self-efficacy) improve patient engagement and treatment adherence in this population.
Harm reduction strategies including safer injection education, syringe service program referrals, naloxone distribution, and basic wound care kits reduce injury without requiring abstinence as a precondition for care.